2nd Annual Biosimilars Summit 2016

2nd Annual Biosimilars Summit 2016

This innovative B2B event will enable the participants to learn about the latest trends of the Biosimilars, commercialization aspects, Regulatory advises and strategies for Biosimilars development. As biosimilars are now being developed and manufactured using todays state of the art technology and techniques, they can potentially also offer some benefits, in addition to cost, over the reference biologics. It is proved that biosimilars could save the U.S. health system close to $44 billion in the next ten years.

Key Practical Learning Points of the Summit:

  • The latest trends of the Biosimilars
  • Successful Commercialization of Biosimilars in Europe and USA
  • Biosimilars In Emerging Markets – Regulatory and Commercial Considerations
  • Industry Partnerships: Key Success Factor to Win in Biosimilar Space
  • Regulatory Advice on Designing Biosimilar Trials
  • Totality of Evidence and What It Means to Clinician
  • Experience of Global Clinical Biosimilar Trials
  • Strategies and competing products for a successful commercialization

  • Powered byVonlanthen Group
  • Project DirectorDiogo Lino Ribeiro (EPM Group)
  • Completed onNovember 2015
  • GenrePharmaceutical
  • Event LocationBerlin, Germany
  • Event Date8-9 February 2016
Visit website